Clinical Trials Logo

Pathological Response clinical trials

View clinical trials related to Pathological Response.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05512481 Recruiting - Melanoma Clinical Trials

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Start date: September 13, 2022
Phase: Phase 2
Study type: Interventional

Neoadjuvant therapy is feasible in stage Ⅱ-Ⅲ melanoma, Carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response.